Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections.

V. J. Wiebe, M. W. DeGregorio

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Amphotericin B therapy is hampered by numerous adverse effects but remains the treatment of choice for disseminated fungal infections. A new form of amphotericin B delivery, which utilizes liposome vesicles, is currently under investigation. Preliminary evidence suggests that liposome-encapsulated amphotericin B has a wider therapeutic index than free amphotericin B and allows for the use of larger total doses. The mechanism of reduced toxicity and enhanced activity may be associated with a liposome donor effect, an erythrocyte protective effect, and a liposome-targeting ability. Liposome-encapsulated amphotericin B tends to be entrapped or taken up by organs rich in reticuloendothelial cells--a particular advantage since disseminated fungal infections localize in these areas. This liposome-encapsulated preparation appears to represent a promising new form of antifungal therapy that may reduce the dose-limiting toxicities of amphotericin B and improve treatment response.

Original languageEnglish (US)
Pages (from-to)1097-1101
Number of pages5
JournalReviews of Infectious Diseases
Issue number6
StatePublished - Nov 1988
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)


Dive into the research topics of 'Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections.'. Together they form a unique fingerprint.

Cite this